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Phospholipase A2Group IIA secretory phospholipase A2 (sPLA2-IIA) of mammalian species is unique among the many structurally
and functionally related mammalian sPLA2 in their high net positive charge and potent (nM) antibacterial activ-
ity. Toward theGram-positive bacteria tested thus far, the global cationic properties of sPLA2-IIA are necessary for
optimal binding to intact bacteria and penetration of themulti-layered thick cell wall, but not for the degradation
of membrane phospholipids that is essential for bacterial killing. Various Gram-positive bacterial species can dif-
fer as much as 1000-fold in sPLA2-IIA sensitivity despite similar intrinsic enzymatic activity of sPLA2-IIA toward
the membrane phospholipids of various bacteria. D-alanylation of wall- and lipo-teichoic acids in Staphylococcus
aureus and sortase function in Streptococcus pyogenes increase bacterial resistance to sPLA2-IIA by up to 100-fold
apparently by affecting translocation of bound sPLA2-IIA to the cell membrane. Action of the sPLA2-IIA and other
related sPLA2 against Gram-negative bacteria is more dependent on cationic properties of the enzyme near the
amino-terminus of the protein and collaboration with other host defense proteins that produce alterations of
the unique Gram-negative bacterial outer membrane that normally represents a barrier to sPLA2-IIA action.
This article is part of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.
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Acute inﬂammatory responses of mammalian hosts to invading bac-
teria include recruitment of polymorphonuclear leukocyte neutrophils
from the bloodstream and mobilization of extracellular antimicrobialphospholipase A2; sPLA2-IIA,
ial Resistance to Antimicrobial
158 MTF, 2501 Crosspark Rd,compounds thatmay originate froma variety of intravascular and extra-
vascular sources [1–3]. The latter often includes a secretory (Group IIA
phospholipase A2 (sPLA2-IIA)) that can function both independently
against many Gram-positive bacteria and in concert with other host de-
fense systems toward both Gram-negative and Gram-positive bacteria
to increase digestion and killing of these bacteria [1,2,4–14]. The
sPLA2-IIA is a member of a family of low Mr (14,000–19,000) secretory
PLA2 with close overall structural and functional (enzymatic) similarity
to related enzymes present in the venoms of snakes and insects and also
in plants [15]. Hallmarks of these proteins include a highly compact
three-dimensional structure that is stabilized by 6–8 disulﬁde bonds
and a calcium-dependent catalytic machinery mediating stereospeciﬁc
3073J.P. Weiss / Biochimica et Biophysica Acta 1848 (2015) 3072–3077hydrolysis of glycerophospholipids at the sn-2 position yielding free
fatty acids and 1-acyl-lyso-phospholipids. Among the ten different se-
cretory sPLA2 expressed by humans, however, there are marked differ-
ences in the regulation of expression, sites of extracellular mobilization,
and preferred biological targets consistent with distinct physiological
roles of the various sPLA2. The sPLA2-IIA is unique in its very high net
charge (up to +17) and antibacterial potency. At nM concentrations,
the sPLA2-IIA can attack both Gram-positive and Gram-negative bacte-
ria, though the latter typically requires the assistance of other host de-
fense proteins to facilitate access of the sPLA2 to phospholipids in the
Gram-negative bacterial envelope (Fig. 1). In contrast, host cells are
highly resistant to sPLA2-IIA, at least under normal resting conditions,
as are viruses whose envelopes are derived from host cell membranes.
Together, theunique antibacterial properties of the sPLA2-IIA and its tar-
get cell selectivity suggest speciﬁc molecular and structural determi-
nants of the antibacterial action of sPLA2-IIA. This review will mostly
focus on those properties that inﬂuence the action of this enzyme on
Gram-positive bacteria.
2. Actions of puriﬁed sPLA2-IIA against Gram-positive bacteria
Testing of the antimicrobial spectrum of sPLA2-IIA has not been ex-
haustive but sufﬁcient to reveal the susceptibility of many different
Gram-positive bacterial species to doses of extracellular sPLA2-IIA achiev-
able in certain settings in vivo [11,12,16–19]. Bacillus subtilis is among the
most sensitive to sPLA2-IIA, with as little as 0.1–1 nM (1.5–15 ng/ml) of
human sPLA2-IIA sufﬁcient to produce 1–3 log killing of 106 bacteria/ml
within 1 h of incubation. Similar effects on Staphylococcus aureus and
Streptococcus agalactiae [20] (Group B streptococci; GBS) generally (but
see below) require 10–100× higher sPLA2-IIA concentrations. Other
Gram-positive bacterial species (e.g., Staphylococcus epidermidis, Strepto-
coccus pyogenes, Enterococcus faecalis) can also be killed by sPLA2-IIA but
require even higher (10–100-fold) doses [17,20]. Where studied, differ-
ences in bacterial sensitivity to the bactericidal effects of sPLA2-IIA parallel
differences in sPLA2-IIA-triggered bacterial phospholipid (PL) degradation
[17,21,22]. A point mutation (D48S) in recombinant human sPLA2-IIA
that disrupts Ca2+ binding needed for catalytic activity ablates both
sPLA2-IIA-induced bacterial PL degradation and killing [9,13]. Bacterial
killing requires rapid and massive PL degradation (N50% of total mem-
brane PL within 30 min) followed almost immediately by loss of the PL
degradation products (free fatty acids and lyso-PL) from the bacterial
membrane to extracellular albumin [21,23,24]. The ability of bacteria
treated with sub-lethal doses of sPLA2-IIA (or otherwise lethal sPLA2-IIA
doses in the absence of albumin) to retain viability despite substantial
degradation of membrane PL suggests a capacity of these treated bacteria
to replace degraded and lost membrane PL by either de novo synthesis of
PL or (in the absence of albumin) recycling of PL breakdownproducts thatGram-negative bacteria
Fig. 1. Schematic structure of envelopes of Gram-negative (left) and Gram-positive (right) bac
negative bacteria, with lipopolysaccharides (LPS) occupying the outer leaﬂet and phospholipidremainwithin the bacterialmembrane [24]. Themechanism(s) of this re-
parative process and its possible role in bacterial resistance to sPLA2-IIA-
mediated killing deserve further study. An autolysin-deﬁcient mutant
strain of S. aureus is as sensitive as the parent strain to the phospho-
lipolytic activity of the sPLA2-IIA but requires several-fold higher sPLA2-
IIA doses to be killed [23]. One possible interpretation of this ﬁnding is
that rapid and extensive loss ofmembrane phospholipids leads to prema-
ture/inappropriate activation of autolysins that help convert potentially
reversible membrane phospholipid loss to irreversible cell wall damage.
Whereas differences in the bactericidal potency of sPLA2-IIA toward
different species of Gram-positive bacteria correlate closely with differ-
ent dose requirements to produce membrane PL degradation in intact
bacteria, these differences do not reﬂect different substrate properties
of the PL of these bacterial species, as judged either by assay of extracted
PL presented as dispersions in aqueous solution or of cell wall-depleted
protoplasts in which PL are presented as integral components of an in-
tact cytoplasmic membrane [21,22]. Thus, the differences in sensitivity
that are observed in variousGram-positive bacteria are a speciﬁc feature
of the interactions of the intact bacteria with sPLA2-IIA and hence, by
implication, distinguishing properties of the cell wall that is assembled
outside of the bacterial membrane.
Themost revealing insights concerning themolecular and structural
determinants of the antibacterial action of sPLA2-IIA toward Gram-
positive bacteria have been obtained in a series of studies of wild-type
(wt) and mutant sPLA2-IIA and wt andmutant S. aureus SA113. As indi-
cated, the most striking physical feature of the sPLA2-IIA is its remark-
ably high net positive charge that is manifest on virtually every
exposed surface of the protein (Fig. 2). Mutational analyses of the
human sPLA2-IIA have conﬁrmed the key role of this property in its ac-
tivity against both B. subtilis and S. aureus (Table 1) [21,25]. Stepwise
decrements in the net (+) charge of human sPLA2-IIA achieved by sub-
stitution of basic amino acids with acidic residues produced a stepwise
reduction in bactericidal potency toward both S. aureus and B. subtilis.
Mutations at different sites of the enzyme had very similar effects on
sPLA2-IIA antibacterial potency, demonstrating the importance of the
global cationicity of the sPLA2-IIA (Fig. 2) in its antibacterial action. Ac-
tivity toward S. aureus (vs. B. subtilis) appears to be somewhatmore de-
pendent on the very high net (+) charge of the sPLA2-IIA, as manifest
both by the greater reduction in potency accompanying diminution of
net charge from +15 to +13 and, conversely, the increase in potency
accompanying an increase in net charge for+15 to+17 (Table 1); [26].
This dependence of the bactericidal potency of the sPLA2-IIA on its
global charge properties parallels changes in PLA2 dose requirements
for producing bacterialmembrane PL degradation and loss. Remarkably,
reduction of the net (+) charge of the sPLA2-IIA by asmuch as 10 charge
units (+15 to +5) does not reduce sPLA2-IIA activity toward the PL of
B. subtilis (Table 1) or S. aureuswhen the PL are presented as part of cellGram-positive bacteria
teria. Note the unique asymmetry to lipid arrangement in the outer membrane of Gram-
s mainly restricted to the inner leaﬂet. Figure is adapted from [47].
90°
Fig. 2. Surface charge distribution in human sPLA2-IIA. Cationic surfaces are represented in
blue, with darker shades of blue signifying regionswith higher net cationic character. Con-
versely, acidic surface regions are represented by shades of red. Note bound substrate an-
alog in upper left image, just left and above center of that image. The four images were
generated by 90° rotations, as indicated.
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Fig. 3. Comparison of binding of [125I] wt and charge variant recombinant human sPLA2-
IIA to wt S. aureus SA113. Incubations contained 5 × 106 bacteria and 50 ng sPLA2-IIA in
1 ml of Hanks buffered salts solution without calcium and magnesium supplemented
with 10 mM HEPES (pH 7.4) and 0.1% albumin. Results shown represent the mean ±
SEM of three experiments, each done in duplicate.
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strongly that the unique cationic properties of the sPLA2-IIA are impor-
tant for initial (surface) interaction of the enzyme with intact Gram-
positive bacteria and/or penetration of the enzyme through the cell
wall but not for its interaction with and degradation of membrane PL
once it has accessed the bacterial cytoplasmic membrane.
Appraising the effects of speciﬁc molecular and structural variables
on initial sPLA2-IIA interactionswith theGram-positive bacterial surface
and underlying cell wall could be confounded by cell wall alterations
that are induced secondary to massive degradation and loss of mem-
brane PL [23]. To preclude this possibility, initial sPLA2-IIA binding has
been measured in the absence of calcium to prevent calcium-
dependent membrane PL degradation. That initial sPLA2-IIA binding
was calcium-independent was established by demonstrating equal
binding of catalytically inactive D48S human sPLA2-IIA in both the pres-
ence and absence of added 1 mM calcium chloride. Comparison of wt
and charge variant [125I]PLA2 binding to S. aureus showed stepwise al-
terations in sPLA2-IIA binding that correlate with the net (+) charge
of the enzyme (Fig. 3). However, effects of sPLA2-IIA net charge on bind-
ing are signiﬁcantly less than effects on antibacterial potency (compare
Table 1, Fig. 3), suggesting additional effects of the cationicity of sPLA2-
IIA on cell wall penetration. To more directly test this hypothesis, dosesTable 1
Role of cationic properties of human sPLA2-IIA in its activity toward intact Gram-positive bacte
Activity (relative to wt sPLA2-IIA
Recombinant human sPLA2-IIA⁎⁎⁎⁎ Net charge S
Wt +15 1
K92E;K87E;K74E;B7E +13 6
K110E.K115E; K38E.K116E;
K10E.K16E;R7E;K16E;K124E.R127D
+11 0
K74E.K87E.R92E;R7E;K10E;K16E +9 b
K38E.K110E.K115E.K116E +7 b
K53E.R54E.R58E.K124E.R127D +5 b
G72K.T103K +17 4
Pig sPLA2-1B –1 b
*All activities weremeasured as dose required to produce 90% bacterial killing (**) or 30% PL de
tional assays.
Activity of b0.1 reﬂects need to use N1000x higher dose of mutant enzyme to produce same ef
⁎⁎⁎⁎ Mutant recombinant human sPLA2-IIAwas prepared byDr. Ning-Sheng Liang (G72K.T103
represent the mean ± SEM of at least three experiments.of wt or charge variant sPLA2-IIA present during the initial incubation of
sPLA2-IIA + S. aureuswithout calcium was adjusted to achieve roughly
equal binding of each sPLA2-IIA species. When the bacteria were
washed to remove unbound PLA2 and incubatedwith calcium, the anti-
bacterial effects of bound sPLA2-IIA clearly correlated with the net
charge of the bound enzyme (+15 N+13 N+11). In sum, the highly
cationic properties of the sPLA2-IIA promote its antibacterial potency
toward Gram-positive bacteria both by promoting initial surface bind-
ing and by increasing the efﬁciency of cell wall penetration of the
bound enzyme to access membrane PL (Fig. 4). These charge-
dependent non-catalytic interactions of the enzyme with the Gram-
positive bacterial envelope make possible the calcium-dependent cata-
lytic degradation of membrane PL that is required for bacterial killing. It
is the ability of the wt sPLA2-IIA to access the membrane PL of intact
Gram-positive bacteria and not its ability to act on the membrane PL
once exposed that differentiates this sPLA2 from other sPLA2 and de-
pends on its unique cationic properties.
Unpublished observations of ours have revealed only slightly greater
calcium-independent sPLA2-IIA binding to B. subtilis than to S. aureus,
strongly suggesting that the remarkable sensitivity of B. subtilis to wtria and isolated membrane protoplasts.
; %)
. aureus** B. subtilis** B. subtilis protoplasts***
00 100 100
± 3 65 ± 9 185 ± 30
.4 ± 0.3 4 ± 3 146 ± 45
0.1 b0.1 135 ± 50
0.1 b0.1 120
0.1 b0.1 170
84 ± 82 122 ± 30 N.T.
0.1 b0.1 100
gradation (***). See references [21,25] for description ofwt andmutant enzymes and func-
fect as wt human sPLA2-IIA.
K) and Drs. R. Koduri andMHGelb (all others). Data shownwere collected by Dr. Liang and
BINDING: Yes (Ca++-independent)
PENETRATION: Yes
ACTIVATION OF AUTOLYSINS: ? 
PL DEGRADATION:  No (Ca++-dependent)
Fig. 4. Summary of required steps in bactericidal action of sPLA2-IIA vs. Gram-positive bac-
teria (e.g., S. aureus) and role of cationic properties of the sPLA2-IIA in each step of the
process.
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Fig. 5. D-alanylation of teichoic acids of S. aureus (SA113) markedly inhibits ability of
bound human sPLA2-IIA to degrade membrane PL of intact bacteria. Binding of [125I] wt
sPLA2-IIA was measured after incubation of bacteria without calcium. Unbound PLA2
was removed by washing and bacteria with bound PLA2 was incubated with calcium to
monitor calcium-dependent PL degradation. Initial incubations contained 5 × 106 bacteria
and 1 ng PLA2 (lower dose of sPLA2-IIA (vs. that used in experiments shown in Fig. 3)
reﬂecting the exquisite sensitivity of the dltA S. aureus to sPLA2-IIA).
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by sPLA2-IIA in these bacteria.
Complementing the insights gained from the mutational and mech-
anistic studies of sPLA2-IIA have been studies of the PLA2 sensitivity of a
variety of envelope mutants of S. aureus derived from SA113. As charge
modiﬁcation of the sPLA2-IIA has little impact on its ability to degrade
membrane PL once the enzyme has access to the bacterial cytoplasmic
membrane, charge modiﬁcation of phosphatidylglycerol (PG), the
major PL species of many Gram-positive bacteria including S. aureus
and B. subtilis, has little effect on the sensitivity to sPLA2-IIA of either in-
tact S. aureus or cell-wall depleted membrane protoplasts [21]. This has
been demonstrated by comparing the sensitivity of wt andmprF S. aure-
us. MprF is a Mr 97,000 integral membrane protein that mediates:
1) modiﬁcation of membrane PG with the cationic amino acid lysine
at the cytoplasmic surface of the cytoplasmic membrane to convert PG
to lysyl PG; and 2) translocation of the newly formed lysyl-PG to the
outer leaﬂet of the membrane [27]; i.e., the membrane leaﬂet that is
accessed by sPLA2 [28]. Whereas conversion of PG to lysyl PG has
been linked to increased bacterial (e.g., S. aureus) resistance to several
different relatively small cationic antimicrobial peptides (CAMPs;
[29]) and also to daptomycin [30],mprF andwt S. aureus show little dif-
ference in sensitivity to sPLA2-IIA and derived membrane protoplasts
are virtually identical in sensitivity to sPLA2-IIA [21].
In marked contrast, D-alanylation of cell envelope teichoic acids
(TA), both peptidoglycan-linked wall teichoic acids (WTA) and
membrane-inserted lipoteichoic acids (LTA) has a profound impact on
the sensitivity of S. aureus (SA113) (intact bacteria but not membrane
protoplasts) to sPLA2-IIA [14,21]. DltA S. aureus are nearly 100-fold
more sensitive to both the phospho-lipolytic and bactericidal actions
of sPLA2-IIA, in comparison to the wt parent strain. Together with the
abundant peptidoglycan polymers that make up the matrix of the cell
wall, WTA and LTA represent the major determinants of the net (−)
charge of the Gram-positive bacterial surface and cell wall [31]. In
S. aureus, the WTA and LTA polymers are comprised of repeating units
of ribitol (WTA) or glycerol (LTA) phosphate [32,33]. Together, WTA
and LTA form a negatively charged lattice bridging the cell membrane
through the cell wall [31]. As such, it is conceivable that they provide
an anionic “ladder” down which the highly cationic sPLA2-IIA couldadvance, displacing as it proceeds less cationic autolysins that are nor-
mally constrained by electrostatic interactions with WTA and LTA [31,
34]. Substitution of WTA and LTA by D-alanine leaves unshielded the
(partial) positive charge of the free α-NH2 group of D-alanine and
thus partially reduces the net (−) charge of the substituted WTA and
LTA polymers [31,35]. The reduced sensitivity of wt vs. dltA S. aureus
to a variety of small CAMPs including Magainin II amide and human
β-defensin 3(HBD-3) has been attributed to the charge-neutralizing ef-
fects of D-alanine substitution [36]. However, these lead to only 3-fold
changes in sensitivity of wt and dltA S. aureus under the same experi-
mental conditions in which sensitivity to sPLA2-IIA is changed 100-
fold [21]. Similar comparative analyses of sPLA2 binding, cell wall pen-
etration, and activity as described above forwt andmutant sPLA2-IIA re-
vealed no effect of D-alanylation of TA on either initial calcium-
independent sPLA2-IIA binding (Fig. 5) or activity against membrane
protoplasts [21]. Remarkably, the marked increase in sensitivity of dltA
S. aureus was equally manifest with wt and mutant human sPLA2-IIA
of lower net (+) charge (+13 or +11 vs. +15 of wt enzyme) [21].
These ﬁndings suggest that the principal effect of D-alanylation of TA
(WTA and LTA) vis a vis sPLA2-IIA action against S. aureus is on penetra-
tion of bound PLA2 to the cell membrane. That this effect of D-
alanylation is manifest irrespective of the net charge of the sPLA2-IIA
may mean that the effect of D-alanine substitution is more a conse-
quence of steric hindrance of cell wall penetration caused by the bulkier
presence of the substituted D-alanine residue (vs. associated divalent
cations) than one based on reduced electrostatic interactions although
3076 J.P. Weiss / Biochimica et Biophysica Acta 1848 (2015) 3072–3077other possible pleiotropic consequences of altered dltA function cannot
be excluded. It should be emphasized that despite the far greater effect
of D-alanylation of TA on the potency sPLA2-IIA (vs. CAMPs) toward wt
S. aureus, themolar potency of sPLA2-IIA towardwt S. aureus is still near-
ly 100× greater than that of the various non-catalytic CAMPs. Whether
or not this reﬂects the greater efﬁciency, even in wt S. aureus, of binding
and cell wall penetration of the wt sPLA2-IIA (vs. CAMPs) or the ability
of even a very small number of molecules of sPLA2-IIA reaching the bac-
terial cytoplasmic membrane to produce lethal damage by virtue of its
catalytic properties is not yet known.
Several other genotypic and phenotypic modiﬁers of sPLA2-IIA po-
tency toward S. aureus have been identiﬁed that support the notion
that the efﬁciency of cell wall penetration is a key determinant of
sPLA2-IIApotency. This includes thegreater sensitivity of: 1) logarithmic
vs. stationary phase bacteria (or bacteria pre-treated with a bacterio-
static antibiotic) [23]; 2) bacteria pre-treated with a sub-inhibitory
dose of a β-lactam antibiotic to reduce cell wall peptidoglycan cross-
linking [23]; and 3) wt vs. tag O S. aureus (lackingWTA) [22]. In each in-
stance, initial PLA2 binding and activity vs. isolated membrane proto-
plasts are essentially the same, strongly suggesting selective effects of
these bacterial modiﬁcations on sPLA2-IIA cell wall penetration. Bound
PLA2 could be nearly fully displaced from the bacteria with 1 M NaCl,
conﬁrming that in each instance bacterial binding of PLA2wasmediated
by initial electrostatic interactions between the cationic protein and an-
ionic sites exposed on the bacterial surface. sPLA2-IIA binding to tagO S.
aureus demonstrated unequivocally that this binding was not depen-
dent on interactionswithWTA, a somewhat surprising result. However,
exchange of substituted D-alanine between WTA and LTA have sug-
gested close physical proximity of these abundant polyanionic polymers
[31,37]; Fig. 1. If so, initial sPLA2-IIA binding to WTA may provide the
most favorable route for translocation of bound PLA2 from the bacterial
surface to the cell membrane. This migration of bound PLA2 may – en
route – lead to localized displacement of autolysin(s) bound to TA, pro-
moting localized autolysin activity (e.g., severing of peptidoglycan
cross-links) and more efﬁcient sPLA2-IIA penetration of the cell wall.
Similar detailed studies have not yet been carried out in other Gram-
positive bacterial species leaving open the question of whether or not
similar mechanistic concepts apply to sPLA2-IIA action against other
Gram-positive bacteria. An important exception has been provided by
recent studies seeking to better understand the basis of the generally
much lower sensitivity of Group A vs. Group B streptococci to sPLA2-
IIA [20]. These studies have revealed an important role of proteins cova-
lently tethered to the cellwall via speciﬁc linkages dependent on sortase
A. Increased sensitivity of SrtA S. pyogenes to the bactericidal action of
sPLA2-IIA was paralleled by increased sPLA2-IIA-triggered bacterial PL
degradation despite greater PLA2 binding to wt bacteria. These ﬁndings
suggest that in S. pyogenes (Group A streptococci), sortase A-dependent
cell wall proteins provide a signiﬁcant impediment to the access of bac-
terial bound PLA2 to the bacterial cytoplasmic membrane.
3. Actions of sPLA2-IIA and other related sPLA2 against
Gram-negative bacteria
In contrast to the ability of nM concentrations of puriﬁed sPLA2-IIA
to act against a variety of Gram-positive bacteria, independent antibac-
terial activity of sPLA toward the Gram-negative bacteria thus far tested
including Escherichia coli, Salmonella typhimurium, Pseudomonas
aeruginosa, and Neisseria meningitidis requires enzyme concentrations
that greatly exceed sPLA2-IIA levels at most or perhaps all body sites
even during inﬂammation [9,38]. However, redistribution of phospho-
lipids from the inner to outer leaﬂet of the Gram-negative bacterial
outer membrane (Fig. 1), as likely induced by sublethal actions of the
neutrophil bactericidal/permeability-increasing protein (BPI) and the
complement membrane-attack complex [1,10] or during shedding of
outer membrane vesicles (“blebs”; [39]) render some of bacterial phos-
pholipids susceptible to sPLA2-IIA. The rate and extent of membranephospholipid degradation by sPLA2-IIA in concert with BPI or the
membrane-attack complex depends on the extent of envelope alter-
ations produced by BPI and themembrane-attack complex and the con-
centration of sPLA2-IIA. These requirements for sPLA2-IIA action toward
the Gram-negative bacteria tested to date are consistent with the re-
stricted access of sPLA2 to phospholipids in the outer leaﬂet of an intact
bilayer structure [28] and the asymmetry in distribution of lipopolysac-
charides (LPS) and phospholipids in the outer membrane of these bac-
teria (Fig. 1; [40]). The extent to which these properties apply to other
Gram-negative bacteria requires further study.
The activity of sPLA2-IIA toward BPI- or membrane-attack complex-
treated Gram-negative bacteria (e.g., Escherichia coli) is also dependent
on the cationic properties of these enzymes that promote non-catalytic
interactions of the enzyme with the altered bacterial surface [41,42].
However, in contrast to the requirements for sPLA2 action against
Gram-positive bacteria, certain functionally related sPLA2 with much
lower global cationic properties (e.g., basic sPLA2 isoform pf Agkistrodon
halys blomhofﬁi venom (net charge of +7); human pancreatic sPLA2-IB
(net charge of +3) that have b0.1% the activity of human sPLA2-IIA to-
ward S. aureus andB. subtilis (LiangNS andWeiss JP; unpublished obser-
vations) display substantial activity toward BPI-treated E. coli [41,42]).
For those two sPLA2, BPI-dependent binding and degradation of phos-
pholipids of E. coli depend on a cluster of basic residues along the
polar face of an alpha-helix near the NH2-terminus that represents a
variable surface region among all sPLA2 [42,43]. Mutational analyses in
recombinant human sPLA2-IIA also support a key role of basic amino
acids in this region in the action of the sPLA2-IIA on BPI- and
complement-treated E. coli, as well as on E. coli ingested by neutrophils
[9].4. Antibacterial actions of sPLA2-IIA in biological ﬂuids, ex vivo
sPLA2-IIA-rich biological ﬂuids, both those that are constitutively
sPLA2-IIA-rich (e.g., tear ﬂuid, seminal plasma; [16,44]) and those in
which the presence of sPLA2-IIA is triggered by either sterile or infec-
tious inﬂammation [6,11,12,18,45], display potent antibacterial activity
against S. aureus and a number of other Gram-positive bacterial species.
sPLA2-IIA levels in inﬂammatory ﬂuids can be as high as 500 nM and in
tear ﬂuids up to 5 μM, sufﬁcient to account for most if not nearly all of
the bactericidal activity of these ﬂuids toward, for example, S. aureus.
Blood plasma and many tissue ﬂuids under resting conditions, by con-
trast, contain b1 nM sPLA2-IIA and no measurable activity toward the
same Gram-positive bacteria. sPLA2-IIA is fully active in ﬂuids contain-
ing physiologic (extracellular) levels of monovalent and divalent
cations.
Studies of sPLA2-IIA-rich inﬂammatory ﬂuids have been instrumental
in showing the potential contribution ofmobilized extracellular sPLA2-IIA
to digestion anddisassembly of bacteria ingested byneutrophils and, in so
doing, the integration ofmobilized cellular andextracellular host defenses
[1,2,9,13,14]. This role has been demonstrated toward both Gram-
negative (e.g., Escherichia coli) and Gram-positive (e.g., S. aureus) bacteria
under biological conditions in which the extracellular sPLA2-IIA alone or
even together with the whole inﬂammatory ﬂuid produced much less
bacterial PL degradation because of limiting levels of extracellular
sPLA2-IIA and/or the intrinsic resistance of the bacterial target. In each cir-
cumstance, the contribution of extracellular sPLA2-IIA could not be
substituted by other human sPLA2, including those (Group V and Group
X sPLA2) present natively in the neutrophil [46], nor by mutants of
sPLA2-IIA that are not active when assayed alone vs. S. aureus or together
with host defense proteins (e.g., neutrophil-derived bactericidal/
permeability-increasing protein, membrane-attack complex of comple-
ment) that perturb theGram-negative bacterial outermembrane, render-
ingGram-negative bacteriamore susceptible to the sPLA2-IIA.Manymore
synergistic interactions involving the sPLA2-IIA, for example with
peptidoglycan-interacting and degrading proteins (e.g., lysozyme)
3077J.P. Weiss / Biochimica et Biophysica Acta 1848 (2015) 3072–3077present in both the cellular and extracellular compartments of
neutrophil-rich exudates, seem likely and deserving much further study.
5. Concluding remarks
The deﬁned nature of the biochemical action of the sPLA2-IIA has
made characterization of its speciﬁc interactions and actions on bacteri-
al targets more amenable than for most antimicrobial compounds that,
by contrast, exert their efforts by non-catalytic mechanisms that are
often difﬁcult to clearly distinguish one from the other.What also stands
out in the antibacterial action of the sPLA2-IIA is the integration of both
initial non-catalytic interactionswith the bacterial envelope that subse-
quently make possible the catalytic events (membrane phospholipid
degradation) that are ultimately linked to bacterial injury and death.
These distinct actions of the enzyme, all required for its potent antibac-
terial action, have made possible identiﬁcation of different structural
and functional attributes of the protein that are needed at different
stages of the enzyme's antibacterial interactions. This, in turn, has pro-
vided an unusually well-deﬁned context in which to determine the
mechanisms by which speciﬁc bacterial properties and components af-
fect sensitivity and resistance to the sPLA2-IIA. Finally, by virtue of the
speciﬁcity of the mechanistic insights gained, clearly different determi-
nants of bacterial sensitivity and resistance to the PLA2 vs. many of the
smaller and non-catalytic cationic antimicrobial peptides have been
able to be appreciated [47], an insight that should be exploited in future
efforts for new drug development.
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